January/February 2019

Department

Pathways in Practice

Use and Refinement of Lung Cancer Clinical Pathways at AdventHealth Cancer Institute

03/06/2019

JCP Editors

In this journal section, we speak with cancer care practitioners about their clinical pathways and pathways programs being used in their practice, how they are being applied in a particular disease state, and what...

In...

03/06/2019

Journal of Clinical Pathways

Column

Clinical Pathways GPS

Pathways for Paying for Rare Disease Treatments

02/22/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

Determining how to pay for the treatment of uncommon yet serious diseases is an important consideration in terms of sustainability and patient access. Novel and expensive therapies will create financial pressure for...

...

02/22/2019

Journal of Clinical Pathways

Editor's Page

Quantifying Resource Use and the Role of Pathways in Reimbursement

02/19/2019

Winston Wong , PharmD;

The delivery of cancer care is inevitably influenced by payment forces. In the ongoing transition from volume- to value-based payment, clinical pathways can serve as an integral tool for successful and streamlined...

The...

02/19/2019

Journal of Clinical Pathways

Editorial

#COA2019: The Most Comprehensive Meeting for Community Oncology

02/19/2019

Nicolas Ferreyros ;

The 2019 Community Oncology Conference will focus on ensuring quality, affordable, and accessible cancer care. This will include 2 days full of learning and networking with community oncology practices and allied...

The...

02/19/2019

Journal of Clinical Pathways

PATIENT PERSPECTIVE

Talking With Patients About Clinical Trials

02/19/2019

Alan J. Balch , PhD, MSc;

Communicating with patients about clinical trials can be a daunting task, especially when many individuals have misconceptions about the nature of clinical trials, confusion about what tasks are involved in...

...

02/19/2019

Journal of Clinical Pathways

News

Conference Coverage

2018 American Society of Hematology Annual Meeting & Exposition

02/19/2019

JCP Editors

The American Society of Hematology (ASH) is the world’s largest professional society serving both clinicians and scientists working in the hematology field with over 17,000 members from almost 100 countries. The...

The...

02/19/2019

Journal of Clinical Pathways

Insights

Interview

What’s on the Horizon for Moffitt’s Clinical Pathways Program

02/19/2019

JCP Editors

To give our readers an in-depth look into how clinical pathways are being implemented, Journal of Clinical Pathways (JCP) is launching Cancer Center Spotlight, a new feature that brings you inside pathways programs...

To...

02/19/2019

Journal of Clinical Pathways

Tools and Resources

Tools for Transformation

What Do We Mean When We Talk About “Clinical Pathways”?

02/19/2019

Gordon Kuntz ;

Gordon Kuntz is a health care consultant and strategic advisor with over 30 years’ experience in a multitude of health care settings, working with payers and providers, and in technology and strategy. He began his...

Gordon...

02/19/2019

Journal of Clinical Pathways

Feature

Research Reports

Resource Utilization and Expenditures During the “Watchful Waiting” Period in Patients With Recurrent Ovarian Cancer

02/19/2019

Karin Travers , DSc;

Adrienne M. Gilligan , PhD;

Paula Smith , MS;

Paul Juneau , MS;

Mohan Bala , PhD;

Brian M. Davis , PhD;

Brooke Harrow , PhD;

Abstract: This article aims to quantify the use of health services during the watchful waiting period after second-line platinum-based therapy among patients with ovarian cancer. Women newly diagnosed with ovarian,...

...

02/19/2019

Journal of Clinical Pathways

Perspectives

Getting “Bundle Ready”: How Provider Organizations Can Design Clinical Pathways in the Context of Bundled Payments

02/19/2019

Joshua M. Liao , MD, MSc, FACP;

Christopher P. Chen , MD, MBA;

Abstract: Clinical pathways can be meaningful tools for improving the quality and value of care. Pathway initiatives are also influenced by payment policy, taking different forms and adopting different emphases...

...

02/19/2019

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

January/February 2019

Department

Column

News

Insights

Tools and Resources

Feature

Current Issue

Special Reports

Subscribe

Volume 5

Specialties

Events

Year Round Education

HMP Global Products